Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma
- 21 March 2018
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 25 (2) , 115-128
Abstract
Hepatocellular carcinoma (HCC) is a major health problem as evidenced by its increasing incidence and high morbidity and mortality rates. Most patients with HCC have underlying liver disease and dysfunction which limits the current therapeutic options. Treatments that spare the liver and destroy the HCC are needed. Targeting transcriptional differences between HCC and liver cells may provide this therapeutic window. In this study, we examine the potential of the Glypican 3 (GPC3) promoter as a targeting strategy. GPC3 is an oncofetal protein belonging to the proteoglycan family which is normally only expressed during fetal development. However, in HCC, the expression of this protein is reactivated. Here, we show that GPC3 is expressed primarily in HCC and not in normal liver lines. We show that the GPC3 promoter can be used to drive expression of significantly more luciferase and eYFP in HCC cell lines compared to normal liver cells. Further, we show that vectors containing cytosine deaminase (CD) under GPC3 promotor control induced significantly more killing of HCC cell lines after treatment with 5-FC compared to normal liver cell lines. These data suggest that transcriptionally targeted delivery of transgene in HCC cells can be achieved using the GPC3 promoter and this targeting strategy produces limited toxicity to normal liver cells.Keywords
This publication has 38 references indexed in Scilit:
- The accessible chromatin landscape of the human genomeNature, 2012
- PaxDb, a Database of Protein Abundance Averages Across All Three Domains of LifeMolecular & Cellular Proteomics, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Cancers with increasing incidence trends in the United States: 1999 through 2008CA: A Cancer Journal for Clinicians, 2012
- MOPED: Model Organism Protein Expression DatabaseNucleic Acids Research, 2011
- Cell-type specific and combinatorial usage of diverse transcription factors revealed by genome-wide binding studies in multiple human cellsGenome Research, 2011
- AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in miceLife Sciences, 2008
- Oncofetal protein IMP3Cancer, 2008
- Selective Inhibition of Hepatoma Cells Using Diphtheria Toxin A under the Control of the Promoter/Enhancer Region of the Human α‐Fetoprotein GeneJapanese Journal of Cancer Research, 2000
- The ontogeny of alpha-fetoprotein gene expression in the mouse gastrointestinal tract.Journal of Cell Biology, 1990